Atezolizumab/bevacizumab/lenvatinibImmune‑related hypopituitarism, primary hypothyroidism and no response: 3 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1961卷 / 1期

关键词：

D O I：

10.1007/s40278-023-41333-x

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：76 / 76

相关论文

共 50 条

[21] NivolumabThyrotoxicosis and hypothyroidism: 3 case reports
Reactions Weekly, 2018, 1724 (1) : 277 - 277
[22] OxcarbazepineCentral hypothyroidism: 3 case reports
Reactions Weekly, 2020, 1830 (1) : 261 - 261
[23] Bevacizumab/corticosteroidsOsteonecrosis: 3 case reports
Reactions Weekly, 2013, 1444 (1) : 11 - 11
[24] Bevacizumab/ranibizumabEndophthalmitis: 3 case reports
Reactions Weekly, 2015, 1576 (1) : 61 - 61
[25] Bevacizumab/fasudilNo response: 10 case reports
Reactions Weekly, 2024, 2022 (1) : 64 - 64
[26] Atezolizumab/bevacizumab/tozinameranFatigue, weakness, abdominal pain, nausea and vomiting: 2 case reports
Reactions Weekly, 2023, 1947 (1) : 84 - 84
[27] Atezolizumab/pembrolizumabMild myocarditis and dermatitis: 3 case reports
Reactions Weekly, 2023, 1944 (1) : 126 - 126
[28] Atezolizumab/ipilimumab/nivolumabLymphocytic colitis : 3 case reports
Reactions Weekly, 2018, 1700 (1) : 47 - 47
[29] Atezolizumab/ipilimumab/pembrolizumabColitis and ulcer: 3 case reports
Reactions Weekly, 2018, 1699 (1) : 40 - 40
[30] Atezolizumab/bevacizumabFatigue and variceal bleed: 3 case reports
Reactions Weekly, 2023, 1968 (1) : 58 - 58

← 1 2 3 4 5 →